We’d love to hear your feedback on this activity. It helps us to continually improve our products.
Division of Nuclear Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA, USA
Dr Graves is a medical physicist, certified by the American Board of Radiology in both nuclear medicine physics and radiation oncology physics, with extensive experience in radiopharmaceutical therapy (RPT), quantitative nuclear imaging, radiation dosimetry and nuclear metrology. read more
His research has focused on development of new medical radioisotopes for imaging and translation of new radiopharmaceutical agents into the clinic. Dr Graves is the primary medical physicist supporting clinical needs of the University of Iowa Comprehensive Radiopharmaceutical Therapy Center of Excellence, USA.
Dr Graves is internationally recognized for his expertise in RPT dosimetry, including nuclear detection and measurement, single photon imaging and optimal clinical use of approved therapies.
Dr Stephen Graves discloses: Advisory board or panel fees from Isotope Technologies Munich, Novartis and Voximetry. Consultancy fees from CDE Dosimetry Services and RayzeBio. Grants/research support from Siemens. Other financial or material support (royalties, patent, etc.) from Wisconsin Alumni Research Foundation.
Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
Ana Kiess is associate professor and residency program director in the Department of Radiation Oncology and Molecular Radiation Sciences at Johns Hopkins University, USA. read more
Her research focuses on new radiopharmaceutical agents, combination therapies, radiopharmaceutical therapy (RPT) dosimetry and toxicities. Her clinical practice includes radiopharmaceutical agents for prostate cancer and other cancers, and she is active in multiple RPT education initiatives.
Dr Ana Kiess discloses: Advisory board or panel fees from Novartis (relationship terminated) Consultancy fees from Novartis (relationship terminated). Grants/research support from Bayer, Merck and Novartis. Speaker’s bureau fees from POINT Biopharma (relationship terminated).
University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA
Jorge A Garcia, MD, FACP, is a professor of medicine and urology at Case Western Reserve University in Cleveland, OH, USA. He is the George and Edith Richman Distinguished Scientist Chair and the current chair of the Solid Tumor Oncology Division at University Hospitals Seidman Cancer Center/Case Comprehensive Cancer Center. Prof. Garcia’s work focuses on genitourinary malignancies. He is the current director of the Genitourinary (GU) Medical Oncology clinical and research programmes at University Hospitals Seidman Cancer Center. read more
Prof. Garcia’s primary research interests encompass prostate, kidney and bladder cancer, with a special focus on developmental therapeutics, immune oncology and targeted therapy.
Prof. Garcia has been a voting committee member for the US Food and Drug Administration Oncology Drug Advisory Committee since 2019, and currently serves as the chair of the committee. He is a member of several professional societies, including the American College of Physicians, Association of Cancer Research, American Society of Clinical Oncology and the American Medical Association. Prof. Garcia is a fellow of the American College of Physicians and has served in the past as a reviewer for the American Board of Internal Medicine.
Prof. Jorge Garcia has no interests/relationships or affiliations to disclose in relation to this activity.
Mayo Clinic, Jacksonville, FL, USA
Jason Starr is an oncologist in the Division of Hematology/Oncology at Mayo Clinic hospital in Jacksonville, FL, USA. His practice is currently focused on caring for patients with gastrointestinal malignancies, with a particular interest and expertise in neuroendocrine neoplasms. read more
Dr Starr served on the National Cancer Institute Neuroendocrine Tumor Task Force from 2018–2021. He is also a member of the North American Neuroendocrine Tumor Society and currently serves as the social media committee co-chair. Dr Starr is also active within the ALLIANCE cooperative group and is a member of the Neuroendocrine Tumor Committee.
Dr Starr is a clinical investigator who serves as a principal investigator (PI) or co-PI on many gastrointestinal cancer clinical trials. Those trials include novel treatments for neuroendocrine neoplasms, including peptide radionuclide radiation therapy. Dr Starr is also passionate about education and is integrally involved with fellow education and wellbeing.
Dr Jason Starr discloses: Advisory board or panel fees from Advanced Accelerator Applications, Canada Expert Now, Ipsen, Natera and TerSera. Consultancy fees from Tempus. Grants/research support from Amgen, Arcus Biosciences and Camurus. Other financial or material support (royalties, patent, etc.) from Camurus.
Oregon Health and Science University Portland, OR, USA
Erik Mittra is a professor of diagnostic radiology at Oregon Health & Science University, Portland, OR, USA, where he serves as chief of the Molecular Imaging and Therapy Section and director of the Targeted Radiopharmaceutical Therapy Program. read more
Dr Mittra is interested in all aspects of nuclear medicine, with a focus on targeted radiopharmaceutical therapies. His research interests are focused on the translation of novel radioisotopes for imaging and therapy. He is involved with the Society of Nuclear Medicine and Molecular Imaging , the North American Neuroendocrine Tumor Society and the Healing NET Foundation, among others.
Dr Erik Mittra discloses: Advisory board or panel fees from Isotope Technologies Munich and TerSera. Consultancy fees from Curium Pharma and Novartis. Grants/research support from Nordic Nanovector and Novartis.